Effect of Underlying Cardiovascular Disease on the Prognosis of COVID-19 Patients; a Sex and Age-Dependent Analysis
Archives of Academic Emergency Medicine,
Vol. 9 No. 1 (2021),
1 Dey 2021
,
Page e65
https://doi.org/10.22037/aaem.v9i1.1363
Abstract
Introduction: Adults with underlying medical disorders are at increased risk for severe illness from the virus that causes COVID-19. This study aimed to compare the effect of underlying diseases on the mortality of male and female patients as a primary objective. We also evaluated the effect of drugs previously used by COVID-19 patients on their outcome.
Methods: This retrospective cohort study was carried out on confirmed cases of COVID-19 who were admitted to a teaching hospital in Tehran, Iran. Data was gathered from patients’ files. Log binomial model was used for investigating the association of underlying diseases and in-hospital mortality of these patients.
Results: A total of 991 patients (mean age 61.62±17.02; 54.9% male) were recruited. Hypertension (41.1%), diabetes mellitus (30.6%), and coronary artery disease (19.6%) were the most common underlying diseases. The multivariable model showed that hypertension (RR = 1.62; 95% CI: 1.22-2.14, p = 0.001) in male patients over 55 years old and coronary artery disease (RR = 2.40; 95% CI: 1.24-4.46, p = 0.009) in female patients under 65 years old were risk factors of mortality. In females over 65 years old, the history of taking Angiotensin Converting Enzyme inhibitors (ACEi) and Angiotensin Receptor Blockers (ARB) (RR = 0.272; 95% CI: 0.17-0.41, p = 0.001) was a significant protective factor for death.
Conclusions: COVID-19 patients with a history of cardiovascular diseases such as hypertension and coronary artery disease, especially those in specific age and sex groups, are high-risk patients for in-hospital mortality. Additionally, a previous history of taking ACEi and ARB medications in females over 65 tears old was a protective factor against in-hospital mortality of COVID-19 patients.
- COVID-19
- Hypertension
- Coronary Artery Disease
- Prognosis
How to Cite
References
Swerdlow DL, Finelli L. Preparation for Possible Sustained Transmission of 2019 Novel Coronavirus: Lessons From Previous Epidemics. JAMA. 2020;323(12):1129-30.
Chowell G, Castillo-Chavez C, Fenimore PW, Kribs-Zaleta CM, Arriola L, Hyman JM. Model parameters and outbreak control for SARS. Emerging infectious diseases. 2004;10(7):1258-63.
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet (London, England). 2020;395(10223):497-506.
WHO (COVID-19) Homepage: World Health Organization; 2021 [updated 18 January 2021; cited 2021 19 January 2021]. Available from: https://covid19.who.int/?gclid=CjwKCAiAgJWABhArEiwAmNVTB3rca0NBb-SkKZ_y0QINR_4PDe-QUL3LMLB8J_qvUyZK1JytaESOixoCopAQAvD_BwE.
People with Certain Medical Conditions: Center for Disease Control and Prevention; 2020 [updated 29-Dec-2020; cited 2021 22-Jan-2021]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html#:~:text=Adults%20of%20any%20age%20with%20the%20following%20conditions%20are%20at,COPD%20(chronic%20obstructive%20pulmonary%20disease).
Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Medicine. 2020;46(5):846-8.
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet. 2020;395(10229):1054-62.
Gami AS, Rader S, Svatikova A, Wolk R, Herold DL, Huyber C, et al. Familial premature coronary artery disease mortality and obstructive sleep apnea. Chest. 2007;131(1):118-21.
Xia F, Zhang M, Cui B, An W, Chen M, Yang P, et al. COVID-19 patients with hypertension are at potential risk of worsened organ injury. Scientific Reports. 2021;11(1):1-10.
Li G, Li H, Lu J. No adequate evidence indicating hypertension as an independent risk factor for COVID-19 severity. Clinical Research in Cardiology. 2021;110(1):146-7.
Izcovich A, Ragusa MA, Tortosa F, Lavena Marzio MA, Agnoletti C, Bengolea A, et al. Prognostic factors for severity and mortality in patients infected with COVID-19: A systematic review. PloS one. 2020;15(11):e0241955.
Peckham H, de Gruijter NM, Raine C, Radziszewska A, Ciurtin C, Wedderburn LR, et al. Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission. Nature communications. 2020;11(1):6317.
Griffith DM, Sharma G, Holliday CS, Enyia OK, Valliere M, Semlow AR, et al. Peer Reviewed: Men and COVID-19: A Biopsychosocial Approach to Understanding Sex Differences in Mortality and Recommendations for Practice and Policy Interventions. Preventing chronic disease. 2020; 16;17:E63..
Pradhan A, Olsson P-E. Sex differences in severity and mortality from COVID-19: are males more vulnerable? Biology of sex Differences. 2020;11(1):1-11.
Abdullah M, Chai P-S, Chong M-Y, Tohit ERM, Ramasamy R, Pei CP, et al. Gender effect on in vitro lymphocyte subset levels of healthy individuals. Cellular immunology. 2012;272(2):214-9.
Hewagama A, Patel D, Yarlagadda S, Strickland FM, Richardson BC. Stronger inflammatory/cytotoxic T-cell response in women identified by microarray analysis. Genes & Immunity. 2009;10(5):509-16.
Lee BW, Yap HK, Chew FT, Quah TC, Prabhakaran K, Chan GS, et al. Age‐and sex‐related changes in lymphocyte subpopulations of healthy Asian subjects: From birth to adulthood. Cytometry: The Journal of the International Society for Analytical Cytology. 1996;26(1):8-15.
Lisse IM, Aaby P, Whittle H, Jensen H, Engelmann M, Christensen LB. T-lymphocyte subsets in West African children: impact of age, sex, and season. The Journal of pediatrics. 1997;130(1):77-85.
Stoica G, Macarie E, Michiu V, Stoica R. Biologic variation of human immunoglobulin concentration. I. Sex-age specific effects on serum levels of IgG, IgA, IgM and IgD. Medecine interne. 1980;18(3):323-32.
Iorga A, Cunningham CM, Moazeni S, Ruffenach G, Umar S, Eghbali M. The protective role of estrogen and estrogen receptors in cardiovascular disease and the controversial use of estrogen therapy. Biology of sex differences. 2017;8(1):1-16.
Matthews KA, Meilahn E, Kuller LH, Kelsey SF, Caggiula AW, Wing RR. Menopause and risk factors for coronary heart disease. New England Journal of Medicine. 1989;321(10):641-6.
Noel Bairey Merz C, Johnson BD, Sharaf BL, Bittner V, Berga SL, Braunstein GD, et al. Hypoestrogenemia of hypothalamic origin and coronary artery disease in premenopausal women: a report from the NHLBI-sponsored WISE study. Journal of the American College of Cardiology. 2003;41(3):413-9.
Shabbir S, Hafeez A, Rafiq MA, Khan MJ. Estrogen shields women from COVID-19 complications by reducing ER stress. Medical Hypotheses. 2020;143:110148.
Calderone A, Menichetti F, Santini F, Colangelo L, Lucenteforte E, Calderone V. Selective Estrogen Receptor Modulators in COVID-19: A Possible Therapeutic Option? Frontiers in Pharmacology. 2020; 15;11:1085.
Stelzig KE, Canepa-Escaro F, Schiliro M, Berdnikovs S, Prakash Y, Chiarella SE. Estrogen regulates the expression of SARS-CoV-2 receptor ACE2 in differentiated airway epithelial cells. American Journal of Physiology-Lung Cellular and Molecular Physiology. 2020; 1;318(6):L1280-L1281
Seeland U, Coluzzi F, Simmaco M, Mura C, Bourne PE, Heiland M, et al. Evidence for treatment with estradiol for women with SARS-CoV-2 infection. BMC medicine. 2020;18(1):1-9.
Pishgahi M, Yousefifard M, Safari S, Ghorbanpouryami F. Electrocardiographic Findings of COVID-19 Patients and Their Correlation with Outcome; a Prospective Cohort Study. Advanced Journal of Emergency Medicine. 2020; 5(2):e17.
Arcos FS, Puche AR, Vera TV. Controversy regarding ACE inhibitors/ARBs in Covid-19. Revista espanola de cardiologia (English ed). 2020;73(6):516.
Lee MM, Docherty KF, Sattar N, Mehta N, Kalra A, Nowacki AS, et al. Renin–angiotensin system blockers, risk of SARS-CoV-2 infection and outcomes from CoViD-19: systematic review and meta-analysis. European Heart Journal-Cardiovascular Pharmacotherapy. 2020; 18:pvaa138; Epub ahead of print
Cao Y, Li L, Feng Z, Wan S, Huang P, Sun X, et al. Comparative genetic analysis of the novel coronavirus (2019-nCoV/SARS-CoV-2) receptor ACE2 in different populations. Cell Discovery. 2020;6:11.
Zhang X, Yu J, Pan L-y, Jiang H-y. ACEI/ARB use and risk of infection or severity or mortality of COVID-19: a systematic review and meta-analysis. Pharmacological research. 2020; 158:104927.
- Abstract Viewed: 932 times
- pdf Downloaded: 397 times
